Alzheimer's disease is the most common form of dementia among older people and is still untreatable. While β-amyloid protein is recognized as the disease determinant with a pivotal role in inducing neuronal loss and dementia, an impaired brain insulin signaling seems to account in part for the cognitive deficit associated with the disease. The origin of this defective signaling is uncertain. Accumulating toxic species of β-amyloid, the so-called oligomers, has been proposed to be responsible for downregulation of neuronal insulin receptors. We have found that the nontoxic form of β-amyloid, the monomer, is able to activate insulin/insulin-like growth factor-1 (IGF-1) receptor signaling and thus behaves as a neuroprotectant agent. Our suggestion is that depletion of β-amyloid monomers, occurring in the preclinical phase of Alzheimer's disease, might be the cause of early insulin/IGF-1 signaling disturbances that anticipate cognitive decline.
|Titolo:||Beta-Amyloid Monomer and Insulin/IGF-1 Signaling in Alzheimer's Disease|
|Data di pubblicazione:||2012|
|Citazione:||Beta-Amyloid Monomer and Insulin/IGF-1 Signaling in Alzheimer's Disease / Giuffrida ML; Tomasello F; Caraci F; Chiechio S; Nicoletti F; Copani A. - 46(2012), pp. 605-613.|
|Appare nelle tipologie:||1.1 Articolo in rivista|